S&P 500   3,281.47 (-3.22%)
DOW   26,576.37 (-3.23%)
QQQ   273.15 (-3.36%)
AAPL   112.39 (-3.61%)
MSFT   204.49 (-4.11%)
FB   269.88 (-4.73%)
GOOGL   1,519.27 (-4.98%)
AMZN   3,179.00 (-3.27%)
TSLA   409.91 (-3.48%)
NVDA   513.61 (-4.15%)
BABA   306.90 (-3.23%)
CGC   18.57 (-0.48%)
GE   7.77 (+9.44%)
MU   50.02 (-3.73%)
AMD   76.86 (-2.56%)
T   26.54 (-1.41%)
F   7.71 (-2.65%)
ACB   3.90 (-2.50%)
GILD   58.56 (-2.42%)
NFLX   486.21 (-0.56%)
NIO   27.22 (-4.29%)
BA   150.07 (-3.33%)
DIS   119.44 (-3.14%)
S&P 500   3,281.47 (-3.22%)
DOW   26,576.37 (-3.23%)
QQQ   273.15 (-3.36%)
AAPL   112.39 (-3.61%)
MSFT   204.49 (-4.11%)
FB   269.88 (-4.73%)
GOOGL   1,519.27 (-4.98%)
AMZN   3,179.00 (-3.27%)
TSLA   409.91 (-3.48%)
NVDA   513.61 (-4.15%)
BABA   306.90 (-3.23%)
CGC   18.57 (-0.48%)
GE   7.77 (+9.44%)
MU   50.02 (-3.73%)
AMD   76.86 (-2.56%)
T   26.54 (-1.41%)
F   7.71 (-2.65%)
ACB   3.90 (-2.50%)
GILD   58.56 (-2.42%)
NFLX   486.21 (-0.56%)
NIO   27.22 (-4.29%)
BA   150.07 (-3.33%)
DIS   119.44 (-3.14%)
S&P 500   3,281.47 (-3.22%)
DOW   26,576.37 (-3.23%)
QQQ   273.15 (-3.36%)
AAPL   112.39 (-3.61%)
MSFT   204.49 (-4.11%)
FB   269.88 (-4.73%)
GOOGL   1,519.27 (-4.98%)
AMZN   3,179.00 (-3.27%)
TSLA   409.91 (-3.48%)
NVDA   513.61 (-4.15%)
BABA   306.90 (-3.23%)
CGC   18.57 (-0.48%)
GE   7.77 (+9.44%)
MU   50.02 (-3.73%)
AMD   76.86 (-2.56%)
T   26.54 (-1.41%)
F   7.71 (-2.65%)
ACB   3.90 (-2.50%)
GILD   58.56 (-2.42%)
NFLX   486.21 (-0.56%)
NIO   27.22 (-4.29%)
BA   150.07 (-3.33%)
DIS   119.44 (-3.14%)
S&P 500   3,281.47 (-3.22%)
DOW   26,576.37 (-3.23%)
QQQ   273.15 (-3.36%)
AAPL   112.39 (-3.61%)
MSFT   204.49 (-4.11%)
FB   269.88 (-4.73%)
GOOGL   1,519.27 (-4.98%)
AMZN   3,179.00 (-3.27%)
TSLA   409.91 (-3.48%)
NVDA   513.61 (-4.15%)
BABA   306.90 (-3.23%)
CGC   18.57 (-0.48%)
GE   7.77 (+9.44%)
MU   50.02 (-3.73%)
AMD   76.86 (-2.56%)
T   26.54 (-1.41%)
F   7.71 (-2.65%)
ACB   3.90 (-2.50%)
GILD   58.56 (-2.42%)
NFLX   486.21 (-0.56%)
NIO   27.22 (-4.29%)
BA   150.07 (-3.33%)
DIS   119.44 (-3.14%)
Log in
NASDAQ:ETTX

Entasis Therapeutics Stock Forecast, Price & News

$1.67
-0.10 (-5.65 %)
(As of 10/28/2020 11:26 AM ET)
Add
Compare
Today's Range
$1.66
Now: $1.67
$1.72
50-Day Range
$1.72
MA: $2.33
$3.03
52-Week Range
$1.68
Now: $1.67
$6.28
Volume3,169 shs
Average Volume189,983 shs
Market Capitalization$59.24 million
P/E RatioN/A
Dividend YieldN/A
Beta1.98
Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel antibacterial products to treat serious infections caused by multi-drug resistant gram-negative bacteria in the United States. It is involved in developing Sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that has completed Phase II clinical trial for the treatment of multi-drug resistant Acinetobacter infections; Zoliflodacin, a novel orally administered molecule that has completed Phase II clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant Gram-negative infections. The company has collaboration agreements with Zai Lab (Shanghai) Co., Ltd. for developing SUL-DUR. Entasis Therapeutics Holdings Inc. was incorporated in 2018 and is based in Waltham, Massachusetts.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.07 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ETTX
CUSIPN/A
CIKN/A
Phone781-810-0120
Employees48

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7 million
Book Value$3.17 per share

Profitability

Net Income$-43,850,000.00

Miscellaneous

Market Cap$59.24 million
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$1.67
-0.10 (-5.65 %)
(As of 10/28/2020 11:26 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ETTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ETTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Entasis Therapeutics (NASDAQ:ETTX) Frequently Asked Questions

How has Entasis Therapeutics' stock price been impacted by Coronavirus?

Entasis Therapeutics' stock was trading at $4.13 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ETTX stock has decreased by 59.6% and is now trading at $1.67.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Entasis Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Entasis Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Entasis Therapeutics
.

When is Entasis Therapeutics' next earnings date?

Entasis Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Entasis Therapeutics
.

How were Entasis Therapeutics' earnings last quarter?

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) announced its quarterly earnings data on Thursday, August, 6th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by $0.06.
View Entasis Therapeutics' earnings history
.

What price target have analysts set for ETTX?

7 analysts have issued 1 year target prices for Entasis Therapeutics' stock. Their forecasts range from $5.00 to $9.00. On average, they expect Entasis Therapeutics' stock price to reach $6.71 in the next year. This suggests a possible upside of 302.1% from the stock's current price.
View analysts' price targets for Entasis Therapeutics
.

Are investors shorting Entasis Therapeutics?

Entasis Therapeutics saw a increase in short interest in the month of October. As of October 15th, there was short interest totaling 442,200 shares, an increase of 46.2% from the September 30th total of 302,500 shares. Based on an average daily volume of 350,000 shares, the short-interest ratio is currently 1.3 days.
View Entasis Therapeutics' Short Interest
.

Who are some of Entasis Therapeutics' key competitors?

What other stocks do shareholders of Entasis Therapeutics own?

Who are Entasis Therapeutics' key executives?

Entasis Therapeutics' management team includes the following people:
  • Dr. Manoussos Perros, Pres, CEO & Director (Age 52, Pay $751.44k)
  • Dr. Michael J. Gutch, CFO, Chief Bus. Officer & Sec. (Age 54, Pay $482.94k)
  • Dr. Ruben Tommasi, Chief Scientific Officer (Age 54)
  • Ms. Elizabeth M. Keiley, Gen. Counsel (Age 54)
  • Ms. Colleen Tucker, Head of HR

When did Entasis Therapeutics IPO?

(ETTX) raised $75 million in an initial public offering (IPO) on Wednesday, September 26th 2018. The company issued 4,400,000 shares at $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers.

What is Entasis Therapeutics' stock symbol?

Entasis Therapeutics trades on the NASDAQ under the ticker symbol "ETTX."

How do I buy shares of Entasis Therapeutics?

Shares of ETTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Entasis Therapeutics' stock price today?

One share of ETTX stock can currently be purchased for approximately $1.67.

How big of a company is Entasis Therapeutics?

Entasis Therapeutics has a market capitalization of $59.24 million and generates $7 million in revenue each year. The company earns $-43,850,000.00 in net income (profit) each year or ($3.33) on an earnings per share basis. Entasis Therapeutics employs 48 workers across the globe.

What is Entasis Therapeutics' official website?

The official website for Entasis Therapeutics is www.entasistx.com.

How can I contact Entasis Therapeutics?

Entasis Therapeutics' mailing address is 35 GATEHOUSE DRIVE, WALTHAM MA, 02451. The company can be reached via phone at 781-810-0120 or via email at [email protected]

This page was last updated on 10/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.